Effect of Eszopiclone on Adherence to CPAP and Severity of Insomnia in Patients With COMISA
60 patients around the world
Available in Brazil
The comorbidity between OSA and insomnia (COMISA) is common. COMISA leads to additive
impairment of quality of sleep and quality of life compared to patients with insomnia or OSA
alone. Patients with COMISA demonstrate worse adherence to CPAP compared to patients with
isolated OSA. The best therapeutic approach for patients with COMISA is still unclear.
Hypnotics have not been tested among patients with COMISA and indication for CPAP.
The investigators will compare the effect of Eszopiclone 3mg or placebo for 14 days on
adherence to CPAP after 30 days and after 6 months. In addition, the investigators will
assess the effect eszopiclone on insomnia severity, quality of life, anxiety.